Recent studies show that different aspects of smoking behavior are associated with the a-5 subunit of the nicotinic acetylcholine receptor (CHRNA5) gene and the gene coding for brain-derived neurotrophic factor (BDNF). This raises the question whether the amount of cigarettes smoked per day has a different genetic background than smoking initiation and what other smoking phenotypes may be relevant. The aim of this study was to replicate these associations in a large population-based sample. We investigated the association with smoking initiation and the number of cigarettes used per day and additional smoking phenotypes in a population-based sample of 2166 participants of Dutch origin. Rs6265 in BDNF was not associated with smoking initiation. This single nucleotide polymorphism was associated with smoking cessation. Rs16969968 in CHRNA5 was associated with the amount of nicotine used and in particular smoking 25 cigarettes or more per day. Overall, the results confirm the involvement of the CHRNA5 gene in the amount of nicotine use and further suggest involvement of the BDNF gene in smoking behavior. Recent studies show that different aspects of smoking behavior are associated with the nonsynonymous single nucleotide polymorphism (SNP) rs16969968 in subunit a5 of the nicotinic acetylcholine receptor (CHRNA5) gene and the Val/Met polymorphism (rs6265) in the gene coding for the brain-derived neurotrophic factor (BDNF). The association of CHRNA5 with smoking quantity has been replicated robustly in numerous studies (Liu et al., 2010) , whereas the association of BDNF with smoking initiation is more tentative (Furberg et al., 2010) . This variety in reported smoking phenotypes raises the question whether the amount of cigarettes used per day (CPD) has a different genetic background than smoking initiation and what other smoking phenotypes may be relevant. We, therefore, investigated the association of BDNF and CHRNA5 with smoking initiation and the number of CPD, as well as additional smoking phenotypes in a large population-based sample.
Recent studies show that different aspects of smoking behavior are associated with the nonsynonymous single nucleotide polymorphism (SNP) rs16969968 in subunit a5 of the nicotinic acetylcholine receptor (CHRNA5) gene and the Val/Met polymorphism (rs6265) in the gene coding for the brain-derived neurotrophic factor (BDNF). The association of CHRNA5 with smoking quantity has been replicated robustly in numerous studies (Liu et al., 2010) , whereas the association of BDNF with smoking initiation is more tentative (Furberg et al., 2010) . This variety in reported smoking phenotypes raises the question whether the amount of cigarettes used per day (CPD) has a different genetic background than smoking initiation and what other smoking phenotypes may be relevant. We, therefore, investigated the association of BDNF and CHRNA5 with smoking initiation and the number of CPD, as well as additional smoking phenotypes in a large population-based sample.
Data were available for 2166 participants that took part in the Utrecht Health Project, a longitudinal cohort study conducted in a newly developed residential area in the Netherlands (Grobbee et al., 2005) . Participants were of Dutch (Caucasian) origin and had four grandparents of Dutch origin. DNA was obtained from peripheral blood lymphocytes using established procedures. The study was approved by the Medical Ethics Committee of the University Medical Center Utrecht, and all participants gave written informed consent. Smoking behavior was assessed by means of a self-rating questionnaire including questions such as: 'Do you currently smoke?', 'If yes; how many cigarettes do you smoke per day' and 'Did you ever smoke?'. We divided current smokers in two categories: smoking less than 25 CPD and smoking 25 CPD or more. This cutoff has 89% specificity for the Diagnostic and Statistical Manual for Mental Disorders-IV edition criteria for nicotine dependence Berrettini et al. (2008) . SNP rs16969968 (CHRNA5) and SNP rs6265 (BDNF) were genotyped using a Taqman SNP genotyping assay on a 7900HT Real-Time PCR System according to the manufacturer's protocol (Applied Biosystems, Foster City, California, USA; assay order number: C__26000428_20 and C__11592758_10). We used two CEPH duplicates per 96-well plate for quality control. Hardy-Weinberg equilibrium was calculated using the w 2 -test. We used a general linear model for the continuous outcome (CPD). For all other analyses, a binary logistic model was used. Genotypes for CHRNA5 and BDNF were used as predictors with the homozygotic wild-type variant as the reference group. Age and sex were entered as covariates. With this sample size, the power was more than 0.90 to detect the reported effect size of both genetic variants (Furberg et al., 2010) with an a value of 0.005 to allow Bonferroni multiple testing correction for 10 tests. Data were analyzed using the Statistical Package for the Social Sciences 17.0 (SPSS Inc., Chicago, Illinois, USA).
Mean age was 40.5 years (standard deviation = 12.7 years; range 19-90 years), 46.9% was men. Of the study population, 54.4% had ever smoked. At the time of assessment, 22.8% smoked, which was 41.5% of the lifetime smokers. Genotype frequencies for CHRNA5 were: AA: 11.8%, AG; 43.1%, GG: 45.1%, and for BDNF: CC: 3.3%, CT: 31.8%, TT: 64.9%, which is in agreement with the Hapmap CEU frequencies (Greenbaum and Lerer, 2009; HapMap, 2010) . Genotypes were in HardyWeinberg equilibrium (P = 0.54 for BNDF and 0.36 for CHRNA5) and the call rate was 96%. All CEPH duplicates gave the same results. The results for CHRNA5 and BDNF are given in Tables 1 and 2 . We did not find an interaction effect of BDNF with CHRNA5.
We did not replicate the finding that SNP rs6265 in the BDNF gene is associated with smoking initiation, although there is a trend in the same direction as in the genome-wide association study data. In this sample, this SNP is associated with smoking cessation with a different effect of the homozygotic C/C variant compared with the heterozygotic C/T variant. We replicated the finding that SNP rs16969968 in the CHRNA5 gene is associated with the amount of nicotine use and in particular smoking 25 CPD or more with an additive effect of the A allele. Clearly, testing of the additional smoking phenotypes introduces a type I error inflation. Correction for multiple testing would render all our finding nonsignificant. On the basis of the primary aim of replicating previous associations, correction for four tests (two variants and two phenotypes) is sufficient. Overall, these results confirm the well-established involvement of the CHRNA5 gene in modifying the amount of nicotine use and further suggest involvement of the BDNF gene in smoking behavior. We demonstrate that different aspects of smoking behavior are associated with different genetic variants and found further evidence for the involvement of BDNF in smoking behavior. More insight in the relevance and meaning of smoking phenotypes seems important. P values were calculated using homozygotic wild-type as reference group. P values below 0.05 are highlighted in bold. 
